Genetically engineered variant of human tissue plasminogen activator (t-PA); expressed in mammalian cells. mol wt ≈50 kDa. Derived by deletion of the fibronectin-like and EGF-like domains and mutation of glutamine for asparagine at position 117. Prepn: G. R. Larsen, T. J. Ahern, WO 8704722; G. R. Larsen, US 5002887 (1987, 1991 both to Genetics Inst.). Thrombolytic efficacy in rats: K. Umemura et al., Eur. J. Pharmacol. 262, 27 (1994). Clinical comparison with alteplase in myocardial infarction: P. den Heijer et al., Circulation 98, 2117 (1998). Review of pharmacology and clinical development: J. Llevadot, R. P. Giugliano, Expert Opin. Invest. Drugs 9, 2689-2694 (2000).
Thrombolytic.
Thrombolytic
This monograph has been retired and is no longer subject to revision or update.